Kiah Purcell, AGPCNP-B

The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.

Robert Mancini, PharmD, explains the viral infections commonly seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.

Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.

Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.

Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.

Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.

Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.

Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.

Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.

Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.